FDA Issues Warning On Voltaren Gel Liver Risks

By Christopher Norton

Law360, New York (December 07, 2009, 4:46 PM ET) -- The U.S. Food and Drug Administration has issued a warning to health care professionals that Novartis AG and Endo Pharmaceuticals Inc.'s topical pain reliever Voltaren Gel carries a risk of potentially fatal liver damage, including organ failure.

Prescribing information for Voltaren Gel has been updated to include new warnings and precautions about the potential for elevation in liver function tests during treatment with all products containing diclofenac sodium, the FDA said Friday.

Voltaren Gel — a trade name for diclofenac sodium gel — is a nonsteroidal...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles